TRPC6 and meningioma: Liao et al. prioritized novel drug targets (XBP1, TTC28 and TRPC6) for meningioma by integrating genome-wide association studies and transcriptomics, with RNA sequencing and molecular docking validating them and revealing expressive characteristics, advancing understanding of meningioma’s molecular landscape.